Grantham, Mayo, Van Otterloo & Co (GMO)
ABBV icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s AbbVie ABBV Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
+885
New +$190K ﹤0.01% 635
2026
Q1 		– Sell
-6,454
Closed -$1.47M – 629
2025
Q4 		$1.47M Hold
6,454
– – ﹤0.01% 438
2025
Q3 		$1.49M Sell
6,454
-338
-5% -$68.8K ﹤0.01% 399
2025
Q2 		$1.26M Buy
6,792
+940
+16% +$175K ﹤0.01% 423
2025
Q1 		$1.23M Sell
5,852
-1,381
-19% -$268K ﹤0.01% 419
2024
Q4 		$1.29M Buy
7,233
+1,054
+17% +$194K ﹤0.01% 409
2024
Q3 		$1.22M Buy
+6,179
New +$1.15M ﹤0.01% 413
2021
Q1 		– Sell
-31,210
Closed -$3.34M – 832
2020
Q4 		$3.34M Buy
31,210
+6,000
+24% +$577K 0.02% 356
2020
Q3 		$2.21M Buy
+25,210
New +$2.37M 0.02% 388
2019
Q3 		– Sell
-18,253
Closed -$1.33M – 719
2019
Q2 		$1.33M Buy
+18,253
New +$1.43M 0.01% 498
2018
Q4 		– Sell
-19,253
Closed -$1.82M – 525
2018
Q3 		$1.82M Sell
19,253
-263,200
-93% -$25M 0.01% 319
2018
Q2 		$26.2M Buy
282,453
+162,253
+135% +$15.8M 0.19% 84
2018
Q1 		$11.4M Buy
120,200
+105,300
+707% +$11.6M 0.07% 146
2017
Q4 		$1.44M Hold
14,900
– – 0.01% 346
2017
Q3 		$1.32M Buy
14,900
+400
+3% +$30.4K 0.01% 360
2017
Q2 		$1.05M Buy
14,500
+9,000
+164% +$605K 0.01% 367
2017
Q1 		$358K Buy
+5,500
New +$346K ﹤0.01% 421
2014
Q2 		– Sell
-66,200
Closed -$3.4M – 489
2014
Q1 		$3.4M Sell
66,200
-217,891
-77% -$11M 0.01% 348
2013
Q4 		$15M Sell
284,091
-235,099
-45% -$11.6M 0.04% 169
2013
Q3 		$23.2M Buy
519,190
+497,890
+2,338% +$22.1M 0.06% 130
2013
Q2 		$881K Buy
+21,300
New +$932K ﹤0.01% 476

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s ABBV Position: Q2 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) opened a new position in AbbVie (ABBV) in Q2 2026: 885 shares worth $223K. The stake represents ﹤0.01% of the portfolio and ranks #635 among its holdings. This is a return to the name: Grantham, Mayo, Van Otterloo & Co (GMO) previously reported a position in ABBV as recently as Q4 2025.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in ABBV in Q2 2013 and has held it in 21 quarters since. The position peaked at $26.2M in Q2 2018. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) held 885 shares of AbbVie worth $223K as of Q2 2026.
  • AbbVie was a new Grantham, Mayo, Van Otterloo & Co (GMO) position in Q2 2026.
  • AbbVie made up ﹤0.01% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q2 2026, its #635 holding.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in AbbVie in Q2 2013 and has held it in 21 quarters since.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s AbbVie position peaked at $26.2M in Q2 2018.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2026, filed 13 Aug 2026.